Group 1 - DiaMedica Therapeutics, Inc. (DMAC) is outperforming the Medical sector with a year-to-date return of 15.5%, compared to the sector average of 7.1% [4] - The Zacks Consensus Estimate for DMAC's full-year earnings has increased by 8.7% over the past 90 days, indicating improving analyst sentiment [4] - DMAC is ranked 2 (Buy) in the Zacks Rank system, which focuses on earnings estimates and revisions [3] Group 2 - DiaMedica Therapeutics, Inc. is part of the Medical - Biomedical and Genetics industry, which consists of 500 stocks and currently ranks 87 in the Zacks Industry Rank [6] - Stocks in the Medical - Biomedical and Genetics industry have gained approximately 1.4% year-to-date, indicating that DMAC is performing better than its peers in this specific industry [6] - Elutia Inc. (ELUT), another stock in the Medical sector, has a year-to-date return of 69% and also holds a Zacks Rank of 2 (Buy) [5]
Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year?